期刊
ANNUAL REVIEW OF NUTRITION
卷 24, 期 -, 页码 201-221出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev.nutr.24.012003.132407
关键词
retinoic acid; retinoic acid receptors; retinoids; cancer
资金
- NCI NIH HHS [CA82770, CA64945] Funding Source: Medline
- NIDCR NIH HHS [DE13139] Funding Source: Medline
- NIDDK NIH HHS [DK44517] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA064945, R01CA082770] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013139] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044517] Funding Source: NIH RePORTER
Studies utilizing experimental animals, epidemiological approaches, cellular models, and clinical trials all provide evidence that retinoic: acid and some of its synthetic derivatives (retinoids) are useful pharmacological agents in cancer therapy and prevention. In this chapter, we first review the current knowledge of retinoic acid receptors (RARs) and their role in mediating the actions of retinoic acid. We then focus on a discussion of RARalpha and acute promyelocytic leukemia followed by a discussion of the role of RARs, in particular RARbeta expression, in other cancer types. Loss of normal RAR function in the presence of physiological levels of RA (either due to alterations in the protein structure or level of expression) is associated with a variety of different cancers. In some cases treatment with pharmacological doses of RA can be effective.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据